ENANTA PHARMACEUTICALS, INC Revenues
ENANTA PHARMACEUTICALS, INC (ENTA) reported Revenues of $44.05 million for the 3-month period ending 2018-03-31, per its 10-Q filed 2018-05-10.
Discontinued › Income Statement
us-gaap:Revenues · last filed 2018-05-10
- ENANTA PHARMACEUTICALS, INC revenues for the quarter ending 2018-03-31 was $44.05M, a 391.67% increase year-over-year.
- ENANTA PHARMACEUTICALS, INC revenues for the quarter ending 2017-12-31 was $38.11M, a 265.83% increase year-over-year.
- ENANTA PHARMACEUTICALS, INC revenues for the quarter ending 2017-09-30 was $75.93M, a 491.29% increase year-over-year.
- ENANTA PHARMACEUTICALS, INC revenues for the quarter ending 2017-06-30 was $7.51M, a 46.27% decline year-over-year.
- ENANTA PHARMACEUTICALS, INC revenues for fiscal 2017 was $102.81M, a 16.48% increase from fiscal 2016.
- ENANTA PHARMACEUTICALS, INC revenues for fiscal 2016 was $88.27M, a 45.13% decline from fiscal 2015.
- ENANTA PHARMACEUTICALS, INC revenues for fiscal 2015 was $160.88M, a 236.98% increase from fiscal 2014.
- ENANTA PHARMACEUTICALS, INC revenues for fiscal 2014 was $47.74M, a 48.94% increase from fiscal 2013.
| Period end | Revenues 3 month | Revenues 6 month | Revenues 9 month | Revenues 12 month |
|---|---|---|---|---|
| 2018-03-31 | $44.05M 10-Q · filed 2018-05-10 | $82.16M 10-Q · filed 2018-05-10 | $158.09M derived: sum of 3 quarters · filed 2018-05-10 | $165.60M derived: sum of 4 quarters · filed 2018-05-10 |
| 2017-12-31 | $38.11M 10-Q · filed 2018-02-09 | $114.04M derived: sum of 2 quarters · filed 2018-02-09 | $121.55M derived: sum of 3 quarters · filed 2018-02-09 | $130.51M derived: sum of 4 quarters · filed 2018-05-10 |
| 2017-09-30 | $75.93M 10-K · filed 2017-12-11 | $83.44M derived: sum of 2 quarters · filed 2017-12-11 | $92.40M derived: sum of 3 quarters · filed 2018-05-10 | $102.81M 10-K · filed 2017-12-11 |
| 2017-06-30 | $7.51M 10-K · filed 2017-12-11 | $16.47M derived: sum of 2 quarters · filed 2018-05-10 | $26.89M 10-Q · filed 2017-08-09 | $39.73M derived: sum of 4 quarters · filed 2018-05-10 |
| 2017-03-31 | $8.96M 10-Q · filed 2018-05-10 | $19.38M 10-Q · filed 2018-05-10 | $32.22M derived: sum of 3 quarters · filed 2018-05-10 | $46.20M derived: sum of 4 quarters · filed 2018-05-10 |
| 2016-12-31 | $10.42M 10-Q · filed 2018-02-09 | $23.26M derived: sum of 2 quarters · filed 2018-02-09 | $37.24M derived: sum of 3 quarters · filed 2018-02-09 | $50.24M derived: sum of 4 quarters · filed 2018-02-09 |
| 2016-09-30 | $12.84M 10-K · filed 2017-12-11 | $26.82M derived: sum of 2 quarters · filed 2017-12-11 | $39.82M derived: sum of 3 quarters · filed 2017-12-11 | $88.27M 10-K · filed 2017-12-11 |
| 2016-06-30 | $13.98M 10-K · filed 2017-12-11 | $26.98M derived: sum of 2 quarters · filed 2017-12-11 | $75.43M 10-Q · filed 2017-08-09 | $89.84M derived: sum of 4 quarters · filed 2017-12-11 |
| 2016-03-31 | $13.00M 10-K · filed 2017-12-11 | $61.45M 10-Q · filed 2017-05-10 | $75.86M derived: sum of 3 quarters · filed 2017-12-11 | $87.46M derived: sum of 4 quarters · filed 2017-12-11 |
| 2015-12-31 | $48.45M 10-K · filed 2017-12-11 | $62.86M derived: sum of 2 quarters · filed 2017-12-11 | $74.46M derived: sum of 3 quarters · filed 2017-12-11 | $131.83M derived: sum of 4 quarters · filed 2017-12-11 |
| 2015-09-30 | $14.42M 10-K · filed 2016-12-09 | $26.02M derived: sum of 2 quarters · filed 2016-12-09 | $83.38M derived: sum of 3 quarters · filed 2016-12-09 | $160.88M 10-K · filed 2017-12-11 |
| 2015-06-30 | $11.60M 10-K · filed 2016-12-09 | $68.97M derived: sum of 2 quarters · filed 2016-12-09 | $146.46M 10-Q · filed 2016-08-09 | $149.10M derived: sum of 4 quarters · filed 2016-12-09 |
| 2015-03-31 | $57.37M 10-K · filed 2016-12-09 | $134.87M 10-Q · filed 2016-05-10 | $137.50M derived: sum of 3 quarters · filed 2016-12-09 | $179.55M derived: sum of 4 quarters · filed 2016-12-09 |
| 2014-12-31 | $77.50M 10-K · filed 2016-12-09 | $80.14M derived: sum of 2 quarters · filed 2016-12-09 | $122.19M derived: sum of 3 quarters · filed 2016-12-09 | $124.35M derived: sum of 4 quarters · filed 2016-12-09 |
| 2014-09-30 | $2.64M 10-K · filed 2015-12-11 | $44.69M derived: sum of 2 quarters · filed 2015-12-11 | $46.85M derived: sum of 3 quarters · filed 2015-12-11 | $47.74M 10-K · filed 2016-12-09 |
| 2014-06-30 | $42.05M 10-K · filed 2015-12-11 | $44.21M derived: sum of 2 quarters · filed 2015-12-11 | $45.10M 10-Q · filed 2015-08-10 | $46.45M derived: sum of 4 quarters · filed 2015-12-11 |
| 2014-03-31 | $2.16M 10-K · filed 2015-12-11 | $3.05M 10-Q · filed 2015-05-08 | $4.40M derived: sum of 3 quarters · filed 2015-12-11 | $6.05M derived: sum of 4 quarters · filed 2015-12-11 |
| 2013-12-31 | $893.00K 10-K · filed 2015-12-11 | $2.24M derived: sum of 2 quarters · filed 2015-12-11 | $3.89M derived: sum of 3 quarters · filed 2015-12-11 | $5.09M derived: sum of 4 quarters · filed 2015-12-11 |
| 2013-09-30 | $1.35M 10-K · filed 2014-12-11 | $3.00M derived: sum of 2 quarters · filed 2014-12-11 | $4.19M derived: sum of 3 quarters · filed 2014-12-11 | $32.05M 10-K · filed 2015-12-11 |
| 2013-06-30 | $1.65M 10-K · filed 2014-12-11 | $2.85M derived: sum of 2 quarters · filed 2014-12-11 | $30.70M 10-Q · filed 2014-08-12 | $32.56M derived: sum of 4 quarters · filed 2014-12-11 |
| 2013-03-31 | $1.20M 10-K · filed 2014-12-11 | $29.05M 10-Q · filed 2014-05-12 | $30.91M derived: sum of 3 quarters · filed 2014-12-11 | $33.45M derived: sum of 4 quarters · filed 2014-12-11 |
| 2012-12-31 | $27.86M 10-K · filed 2014-12-11 | $29.72M derived: sum of 2 quarters · filed 2014-12-11 | $32.26M derived: sum of 3 quarters · filed 2014-12-11 | $68.82M derived: sum of 4 quarters · filed 2014-12-11 |
| 2012-09-30 | $1.86M 10-K · filed 2013-12-18 | $4.40M derived: sum of 2 quarters · filed 2013-12-18 | $40.97M derived: sum of 3 quarters · filed 2013-12-18 | $41.71M 10-K · filed 2014-12-11 |
| 2012-06-30 | $2.54M 10-K · filed 2013-12-18 | $39.11M derived: sum of 2 quarters · filed 2013-12-18 | $39.85M 10-Q · filed 2013-08-12 | |
| 2012-03-31 | $36.56M 10-K · filed 2013-12-18 | $37.31M 10-Q · filed 2013-05-15 | ||
| 2011-12-31 | $741.00K 10-K · filed 2013-12-18 | |||
| 2011-09-30 | $41.88M 10-K · filed 2013-12-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Emergent BioSolutions Inc. (EBS) | United States | $0.347B | -2.43 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |